Millennium Management
BDRX

Millennium Management’s Biodexa Pharmaceuticals BDRX Stock Holding History

Millennium Management’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2
Closed -$14K – 6120
2023
Q2 		$14K Buy
+2
New +$35.7K ﹤0.01% 5699
2023
Q1 		– Hold
0
– – – 5949

Other funds holding BDRX

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management's BDRX Position: Q3 2023 in Review

Millennium Management sold out of Biodexa Pharmaceuticals (BDRX) in Q3 2023, closing a stake of 2 shares — an estimated $14K sold.

Millennium Management first reported a position in BDRX in Q2 2023 and held it in 1 quarter. The position peaked at $14K in Q2 2023. 1 fund tracked by Wall St. Rank holds BDRX as of Q3 2023.

  • Millennium Management reported no remaining Biodexa Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Millennium Management sold 2 Biodexa Pharmaceuticals shares in Q3 2023, an estimated $14K.
  • Millennium Management first reported a position in Biodexa Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Millennium Management's Biodexa Pharmaceuticals position peaked at $14K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q3 2023.

Based on Millennium Management's 13F filing for Q3 2023, filed 14 Nov 2023.